anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. Technical Result Reduce of the level of cholesterol in plasma.            2. Essence A method comprises treating the initial material of plant origin by the mixture of solvents and subsequent purifying the product, then mixing pulping soap with the mixture of solvents comprising ketone structure RCORi, wherein R and Ri are alkyl selected from C5 – C10 carbons and water and does not contain spirit; receiving a creamy precipitate at temperature 25-1500C and extracting phytosterol composition after its purifying.                    3. Field of Application Chemistry, medicine.
The substantially water free tablet when chewed in the mouth forms a self-foaming paste containing stannous fluoride. The tablet contains less than about 50 % by weight of a composition producing carbon dioxide when mixed with the saliva in the mouth, and greater than about 35 % by weight of a substantially insoluble filling and polishing composition, and a wetting and foam stabilizing composition which forms the paste. Preferably the filling and polishing composition comprises greater than about 50 % of said tablet and said carbon dioxide producing composition comprises less than about 25 % by weight of said tablet. The tablet is water free to prevent degradation of the stannous fluoride before use. A tablet is chewed to form the paste. The paste is swished around in the mouth and between the teeth to perform a mechanical cleaning action and to bring the stannous fluoride in contact with the tooth surfaces. The tablet is then swallowed. Twice a day use provides an anti-caries and anti-plaque effect greater than that heretofore achieved by any dental hygiene product.
Disclosed are compounds that include two or more haptens conjugated by a spacer or a carrier. The haptens may include diethylenetriaminepentaacetate (DTPA), histimine-succinyl-glutamine (HSG), or combinations of DTPA and HSG. The compound also includes an effector molecule which may be conjugated to one or more of the haptens, the spacer/carrier, or both. The effector molecule may be conjugated by a number of linkages including an ester linkage, an imino linkage, an amino linkage, a sulfide linkage, a thiosemicarbazone linkage, a semicarbazone linkage, an oxime linkage, an ether linkage, or combinations of these linkages. The compounds can be used in combination with a binding molecule having one arm that binds the compounds, for treating and/or diagnosing a disease or condition that may lead to a disease in a patient. Also disclosed are methods of synthesizing the compounds and/or precursors of the compounds.
FIELD: medicine, narcology. SUBSTANCE: method involves orally administration of water-soluble copper nitrate and chloride salts on the basis of daily requirement as trace element 0.26-0.3% mg/kg. Method ensures to enhance effectiveness of treatment due to enhancement of level of own endogenous endorphins. Invention can be used for correction of psychophysiological state of patients with narcomania. EFFECT: improved and enhanced method of treatment. 5 ex
The invention relates to a nano silver antibiotic wide waistband for preventing and treating chronic nephritis, which belongs to the technical field of the production of healthy textile fibre fabrics. The chronic nephritis belongs to one of clinically refractory diseases. One traditional antibiotic only can kill 6 pathogenic biological bacteria. As the drug resistance and the drug toleration of the antibiotic are increasingly strong, bacterial viruses are increasingly difficult to remove. Nano silver can kill 650 pathogenic biological bacteria and can effectively control refractory drug-resistant strains, and the antibiotic rate reaches 99.99%. The nano silver antibiotic wide waistband for preventing and treating the chronic nephritis is a textile fibre fabric which uses nano antimicrobial agent of selenium, germanium, zinc and silver and a zeolite type antimicrobial agent, also has a far-infrared radiant substance and is prepared by adding nano micropowder obtained by evenly mixing an aloe dampness-keeping factor, medical stone and a traditional Chinese medicine preparation into spinning liquid. By percutaneous osmosis and absorption, the invention achieves the effects of safety, environmental protection, broad spectrum, lasting and effective effect, bacterium resistance, sterilization and disease treatment.
Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with \< 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.
This study first investigated how FNDC5 affected the development of oral cancer and revealed the role of FNDC5 in the migration and invasion of oral cancer. The present work evaluated differential FNDC5 expression within oral cancer samples versus matched non-carcinoma samples based on GEO database analysis and immunohistochemistry. We then generated oral cancer cell lines with FNDC5 overexpression and knockdown to determine the role of altered FNDC5 expression in the migration and invasion of oral cancer. PI3K inhibitor was used for investigating the possible mechanism underlying FNDC5 during EMT of oral cancer. Finally, these in-vitro results were validated using the lung metastatic nude mouse model. According to our results, FNDC5 level markedly decreased within oral cancer compared with adjacent samples and FNDC5 overexpression inhibited migration, invasion as well as EMT of oral cancer, while FNDC5 knockdown promoted oral cancer cell EMT. In addition, PI3K inhibitors blocked the induction of oral cancer cells EMT by FNDC5 knockdown. In vivo experiments further demonstrated the above results. This work is the first to illustrate the impact of FNDC5 on inhibiting migration and invasion of oral cancer, and our results suggest that FNDC5 affects EMT of oral cancer via the inhibition of PI3K/Akt/Snail pathway.
LOR-253 HCl will be given in ascending doses until the maximum administered dose or appropriate target dose is reached. A biomarker study of up to 10 patients will be conducted upon achieving appropriate dose level.
Caspofungin acetate for injection is a sterile, lyophilized product for intravenous (IV) infusion that contains a semisynthetic lipopeptide (echinocandin) compound synthesized from a fermentation product of Glarea lozoyensis. Caspofungin acetate is an echinocandin antifungal that inhibits the synthesis of β (1,3)-D-glucan, an integral component of the fungal cell wall.

  
  


Caspofungin acetate is 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine] pneumocandin B0 diacetate (salt). Caspofungin acetate for injection 50 mg vial contains 50 mg of caspofungin equivalent to 55.5 mg of caspofungin acetate. Caspofungin acetate for injection 50 mg vial also contains 39 mg sucrose, 26 mg mannitol, 2 mg glacial acetic acid added as a buffering agent, and sodium hydroxide added as a pH adjuster ingredient. Caspofungin acetate for injection 70 mg vial contains 70 mg of caspofungin equivalent to 77.7 mg of caspofungin acetate. Caspofungin acetate for injection 70 mg vial also contains 54 mg sucrose, 36 mg mannitol, 2.7 mg glacial acetic acid added as a buffering agent, and sodium hydroxide added as a pH adjuster ingredient.  
Caspofungin acetate is a hygroscopic, white to off-white powder. It is freely soluble in water and methanol, and slightly soluble in ethanol. The pH of a saturated aqueous solution of caspofungin acetate is approximately 6.6. The empirical formula is C52H88N10O15•2C2H4O2 and the formula weight is 1213.42. The structural formula is:
The study is a cluster-randomized intervention trial with clinical practices serving as the unit of randomization and analysis. The investigators are testing two increasingly intensive interventions compared to a minimal intensity/Usual Care Group. Group 1 (Usual Care) includes determination of BMI percentile at baseline, 1-year, and 2-year follow-up. Usual Care (UC) practitioners provide parents with educational materials and routine care. UC pediatricians and their study staff received a ½ day study orientation session which included a brief CME-type workshop addressing obesity treatment.. Group 2 (Pediatric Practitioner only) includes the same assessment points as UC. In addition, Group 2 Pediatric Practitioners (PPs) received 2 days of in-person training in Motivational Interviewing (MI) and Behavior Therapy (BT) as well as an interactive DVD MI booster training system focusing on pediatric obesity. PPs in Group 2 are asked to schedule 3 proactive counseling sessions with a parent of the index child in Year 1 and one additional "booster" visit in year 2. To guide their counseling they are provided with a food and activity screening tool. In addition, Group 2 practices are provided with educational materials written in a style consistent with Motivational Interviewing and Self Determination Theory. Unlike in Group 1, where all of the educational materials are provided proactively to each parent, in Groups 2 and 3, materials are distributed on a more selective tailored basis depending on parent needs. Group 3 (PP+RD) includes the same intervention components as Group 2, but adds MI-based counseling from a trained and registered dietitian (RD) who is linked to that practice. RDs deliver 6 MI-based counseling sessions over 2 years. The intervention is front loaded with 4 sessions in Year 1 and the remaining 2 in Year 2. The RD sessions are delivered both in-person (required for visit 1) and optionally by telephone or in-person, subsequently. Similar to MDs, RDs received 2.0 days of in-person MI and BT training, and the interactive DVD MI booster training system.
Participants will be fitted with either the Microlife WatchBP O3 ambulatory blood pressure monitoring device or instructed on how to use the Microlife WatchBP Home N home blood pressure device, depending on which they are assigned to complete first. The order in which participants undergo ambulatory or home blood pressure monitoring will be assigned through a random number generator.
The invention concerns a human regulatory transcript factor 9 and polynucleotide encoding it. The invention also concerns the process of producing the polypeptide by recombinant DNA technique. The methods for treating many diseases e.g. malignant tumor, hemopathy, disorder of embryo development, infection of HIV, immunological diseases and a variety of inflammations etc. utilizing the polypeptide are disclosed. The invention discloses the antagonist against the polypeptide and therapeutics thereof. The invention also discloses the uses of the polynucleotide, which encodes a human regulatory transcript factor 9.
The investigators hypothesize that combining the biomarkers with electronic health risk score will impact improvement in AKI risk stratification. Using a real time, externally validated electronic health record based AKI risk score, the investigators will enroll patients who are at high risk for the impending development of KDIGO Stage 2 AKI (top 10% of risk). Once identified and enrolled, patients will have blood and urine samples collected over the next 3 days. The investigators will recruit two cohorts of 400 patients across the two institutions. In the development cohort, the investigators will see if adding urinary or blood biomarkers of AKI can improve the ability of EHR-risk score to predict the development of Stage 2 AKI and other outcomes. The investigators will compare the area under the receiver operator characteristic curve (AUC) for the risk score alone versus the risk score plus biomarkers. The investigators will then seek to validate our findings in a separate cohort of 400 patients.
Once-daily extended-release tacrolimus (LCPT) exhibits increased bioavailability versus immediate-release (IR-TAC) and prolonged release (PR-TAC) tacrolimus. Improvements in tremor were previously reported in a limited number of kidney transplant patients who switched to LCPT. We conducted a non-interventional, non-randomized, uncontrolled, longitudinal, prospective, multicenter study to assess the impact of switching to LCPT on tremor and quality of life (QoL) in a larger population of stable kidney transplant patients. The primary endpoint was change in The Essential Tremor Rating Assessment Scale (TETRAS) score; secondary endpoints included 12-item Short Form Survey (SF-12) scores, tacrolimus trough concentrations, neurologic symptoms, and safety assessments. Subgroup analyses were conducted to assess change in TETRAS score and tacrolimus trough concentration/dose (C0/D) ratio by prior tacrolimus formulation and tacrolimus metabolizer status. Among 221 patients, the mean decrease of TETRAS score after switch to LCPT was statistically significant (p < 0.0001 vs. baseline). There was no statistically significant difference in change in TETRAS score after switch to LCPT between patients who had received IR-TAC and those who had received PR-TAC before switch, or between fast and slow metabolizers of tacrolimus. The overall increase of C0/D ratio post-switch to LCPT was statistically significant (p < 0.0001) and from baseline to either M1 or M3 (both p < 0.0001) in the mITT population and in all subgroups. In the fast metabolizers group, the C0/D ratio crossed over the threshold of 1.05 ng/mL/mg after the switch to LCPT. Other neurologic symptoms tended to improve, and the SF-12 mental component summary score improved significantly. No new safety concerns were evident. In this observational study, all patients had a significant improvement of tremor, QoL and C0/D ratio post-switch to LCPT irrespective of the previous tacrolimus formulation administered (IR-TAC or PR-TAC) and irrespective from their metabolism status (fast or slow metabolizers).
The method for the assessment of adenyl cyclase activity in isolated blood cells comprises the reaction of the isolated blood cells in suspension with the inducer of adenyl cyclase activity. The standard system representing red blood cell suspension in the acidified isotonic saline solution of sodium chloride is used with this aim. The standardized suspension of red blood cells (optical density of 0.70) in a volume of 0.5 ml is added to the cuvette containing 20 ?l of adrenalin solution. The mixture is incubated for 2 min. Then 0.2 ml of hydrochloric acid solution (2.10-3 M/L) prepared in the isotonic saline solution of sodium chloride is added. The results of the assay are recorded photometrically using the self-recording unit connected with millivoltmeter.
The present invention belongs to the field of biotechnology, and relates to a surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment, encoded gene and use thereof. According to the invention, the surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is filtered from a base through establishing a Toxoplasma gondii human immunoglobulin, ELISA, diluting the prothrombin time, sequencing analysis, etc. Through expression purifying and authenticating, the human antigen Fab fragment is authenticated to specifically identify the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii and have higher affinity with the tachyzoite-bradyzoite recombination SAG1 of Toxoplasma gondii, for being identified with the specificity of Toxoplasma gondii tachyzoite-bradyzoite. The human antigen Fab fragment of the invention does not contain Fc segment and does not activate the alexin or cause the histopathological damages of human immune response, etc. when the function of restricting the invasion of Toxoplasma gondii to the host cell is exerted. The surface antigen 1 (SAG1) of Toxoplasma gondii human antibody Fab fragment is safe and reliable when applied for the human body. The antigen medicine for treating toxoplasmosis or the antigen targeted medicine can be prepared.
Relapsed and/or refractory (R/R) primary central nervous system lymphoma (PCNSL) has a poor prognosis. A 57-year-old man diagnosed with PCNSL achieved a complete response by high-dose methotrexate-based chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT). The disease was not cured, so he was treated with the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel after the third relapse. However, the disease relapsed again 28 days after CAR T-cell therapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was attempted as curative therapy after bridging with second ASCT and tirabrutinib monotherapy. Although a temporary response was achieved, the disease relapsed 98 days after allo-HSCT. While receiving tirabrutinib for relapse after allo-HSCT, the patient developed acute respiratory failure due to transplant-related toxicity and post-transplant thrombotic microangiopathy. He died 175 days after allo-HSCT. Although various treatments for PCNSL have been investigated in recent years, the treatment strategy for R/R PCNSL has not been established. Further studies are warranted to improve the outcomes of patients with R/R PCNSL.
SYSTEMS AND METHODS FOR REMOTELY PROCESSING DATA COLLECTED BY A DRUG DELIVERY DEVICE Systems and methods are disclosed for processing sensor data collected by a drug delivery device with an external computing device. The drug delivery device may include a reservoir and a delivery cannula having a proximal end in fluid communication with the reservoir and a distal end to be received within a patient. The drug delivery device may further include one or more sensors configured to generate sensor data representative of a condition and/or operational state of the drug delivery device, and a communication module configured to transmit information to the external computing device. The external computing device may process the information received from the drug delivery device according to information stored in a memory of the external computing device to determine the condition or the operational state of the drug delivery device and/or generate instructional or informational prompts to be displayed to a user or patient. Fig. 3
BACKGROUND: Locally infiltrating (T4) differentiated thyroid carcinomas (DTC) represent a challenge. Surgical strategy and adjuvant therapy should be planned balancing morbidity and oncologic outcome. A series of patients with T4 DTC who underwent multidisciplinary evaluation and treatment is reported. The main study endpoints were the oncologic outcome, complication rates, and risk factors for tumor recurrence.
PATIENTS AND METHODS: All DTC cases operated between 2009 and 2021 were reviewed and T4 DTC cases were identified. En bloc resection of inferior laryngeal nerve (ILN), tracheal, and/or internal jugular vein (IJV) was performed in cases of massive infiltration. In cases of pharyngoesophageal junction (PEJ) invasion, the shaving technique was always applied.
RESULTS: Among 4775 DTC cases, 60 were T4. ILN infiltration was documented in 45 cases (en bloc resection in 9), tracheal infiltration in 14 (tracheal resection in 2), PEJ invasion in 11 (R0 resection in 7 cases and < 1 cm residual tissue in 4 cases), IJV resection in 6, and laryngeal in 2. In total, 11 postoperative ILN palsy, 23 transient hypoparathyroidisms, and 2 hematomas requiring reoperation were registered. Final histology showed 7 pN0, 22 pN1a, and 31 pN1b tumors. Aggressive variants were observed in 47 patients. All but 1 patient underwent radioiodine treatment, 12 underwent adjuvant external beam radiation therapy (EBRT), and 2 underwent chemotherapy. At a median follow-up of 58 months, no tumor-related death was registered, and seven patients required reoperation for recurrence. Tracheal invasion was the only significant factor negatively impacting recurrence (p = 0.045).
CONCLUSIONS: A multidisciplinary approach is essential for the management of T4 DTC. Individualized and balanced surgical strategy and adjuvant treatments, in particular EBRT, ensure control of locally advanced disease with acceptable morbidity.
<P>PROBLEM TO BE SOLVED: To provide at least one new amino acid sequence for such peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class I, in order to develop a tumor vaccine.  <P>SOLUTION: The tumor-associated peptide contains an amino acid sequence selected from specific sequences. The peptide has the ability to bind to the molecule of the human major histocompatibility complex (MHC) class I. Also, the use of the peptides for producing a medicament and for treating tumorous diseases is provided. Further, a pharmaceutical composition, which contains at least one of the peptides, is provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention provides methods and compositions for inducing  and maintaining  tolerance to epitopes or antigens containing  the epitopes. The compositions include expression cassettes and vectors including DNA sequences coding for a fusion immunoglobulin operably linked to transcriptional and translational control regions functional in a hemopoietic or lymphoid cell.  The  fusion immunoglobulin includes at least one heterologous tolerogenic epitope at the N-terminus variable region of the immunoglobulin. Cells stably transformed with the expression vector are formed and used to produce  fusion immunoglobulin.  The invention also provides methods for  screening  for novel tolerogenic epitopes and for inducing and maintaining tolerance.  The methods of the  invention are useful in the diagnosis and treatment of autoimmune or allergic immune responses.
A cosmetic deodorizing and insect repelling agent includes at least one organic electro-neutral salt obtained by the reaction of equimolecular amounts of anionic surface-active and cationic surface-active compounds, the cationic compounds containing only one nitrogen atom-a quaternary nitrogen atom-per molecule, both said anionic and said cationic surface-active compounds containing at least six carbon atoms per molecule.  Cosmetic agent means a lotion, ointment or powder manufactured specifically for application to the skin with the object of improving its appearance, e.g. face and shaving lotions, skin oils, powders and creams.  The cationic compounds are ammonium compounds and must contain at least one aliphatic, cycloaliphatic or aliphatic aromatic radical having at least 6 to 20 carbon atoms.  They may also contain hetero atoms or groups other than nitrogen. Specified cationic compounds include, inter alia, trimethyl hexyl ammonium bisulphate, dimethyl dodecyl benzyl ammonium chloride, hexylquinolinium chloride, octadecoxycarbomethyl trimethyl ammonium chloride, octadecylthiomethyl triethyl ammonium bisulphate, abietyloxycarbomethyl quinolinium bromide. Specified anionic surface-active compounds include compounds of the aliphatic cycloaliphatic or aliphatic aromatic series containing at least one acid forming group capable of being neutralized by inorganic bases to form water-soluble salts. Specified compounds include, inter alia, alkyl sulphates and sulphonates, salts of dialkyl or dialkylaryl disulphonimides or sulphocarbonimides, fatty acid salts, salts of the condensation products of higher molecular weight carboxylic acid or sulphonic acid halides with proteins and similar compounds and may contain hetero atoms or atom groups.  The electro-neutral salts may be worked in during manufacture or after manufacture of the said agents or incorporated by reaction of the starting components in the said agents.  In an example, a skin cream consists, in parts by weight, of an alcohol mixture of cetyl and myristyl alcohols, 135; glycerol, 6; sodium lauryl sulphate (in aqueous solution), 2.5; salt from dimethyl hexa hydrophenyl dodecyl ammonium chloride and hexadecyl sodium sulphate, 10; perfume.